Veru (VERU) Total Current Liabilities (2010 - 2026)
Veru (VERU) posted quarterly Total Current Liabilities of $5.4 million for Q1 2026, down 4.1% year-over-year from $5.6 million in Q1 2025, and down 24.4% quarter-over-quarter from $7.1 million in Q4 2025.
Veru (VERU) Total Current Liabilities (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Total Current Liabilities for 17 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 4.1% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (down 4.1% YoY), while the FY2025 annual figure was $7.8 million, down 34.4% from the prior year.
- Total Current Liabilities slipped to $5.4 million in Q1 2026 per VERU's latest filing, from $7.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $38.7 million in Q3 2022 and bottomed at $5.4 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $17.1 million across 5 years, with a median of $11.9 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 168.85% — and 2024, when it tumbled 72.07%.
- Veru's Total Current Liabilities stood at $37.5 million in 2022, then tumbled by 55.64% to $16.6 million in 2023, then slumped by 61.81% to $6.3 million in 2024, then advanced by 12.28% to $7.1 million in 2025, then fell by 24.4% to $5.4 million in 2026.
- Business Quant data shows VERU's Total Current Liabilities at $5.4 million in Q1 2026, $7.1 million in Q4 2025, and $7.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 630.93 Mn |
| 10 | Veru | 61.31 Mn | 35.52 Mn | - | 6.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.16 Mn |
| Mar 31, 2026 | 5.39 Mn |
| Dec 31, 2025 | 7.13 Mn |
| Sep 30, 2025 | 7.79 Mn |
| Jun 30, 2025 | 6.68 Mn |
| Mar 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 6.35 Mn |
| Sep 30, 2024 | 11.87 Mn |
| Jun 30, 2024 | 10.62 Mn |
| Mar 31, 2024 | 9.57 Mn |
| Dec 31, 2023 | 16.62 Mn |
| Sep 30, 2023 | 17.81 Mn |
| Jun 30, 2023 | 26.44 Mn |
| Mar 31, 2023 | 34.25 Mn |
| Dec 31, 2022 | 37.48 Mn |
| Sep 30, 2022 | 38.71 Mn |
| Jun 30, 2022 | 27.81 Mn |
| Mar 31, 2022 | 21.18 Mn |
| Dec 31, 2021 | 13.94 Mn |
| Sep 30, 2021 | 15.77 Mn |